Logo image of AXSM

AXSOME THERAPEUTICS INC (AXSM) Stock Fundamental Analysis

NASDAQ:AXSM - Nasdaq - US05464T1043 - Common Stock - Currency: USD

102.55  -7.13 (-6.5%)

After market: 102.5 -0.05 (-0.05%)

Fundamental Rating

3

Overall AXSM gets a fundamental rating of 3 out of 10. We evaluated AXSM against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AXSM have multiple concerns. AXSM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AXSM had negative earnings in the past year.
AXSM had a negative operating cash flow in the past year.
In the past 5 years AXSM always reported negative net income.
AXSM had a negative operating cash flow in each of the past 5 years.
AXSM Yearly Net Income VS EBIT VS OCF VS FCFAXSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

AXSM has a Return On Assets (-46.64%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -523.02%, AXSM is doing worse than 77.84% of the companies in the same industry.
Industry RankSector Rank
ROA -46.64%
ROE -523.02%
ROIC N/A
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
AXSM Yearly ROA, ROE, ROICAXSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

AXSM has a Gross Margin of 91.49%. This is amongst the best in the industry. AXSM outperforms 95.36% of its industry peers.
AXSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AXSM Yearly Profit, Operating, Gross MarginsAXSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AXSM has more shares outstanding than it did 1 year ago.
AXSM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AXSM is higher compared to a year ago.
AXSM Yearly Shares OutstandingAXSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AXSM Yearly Total Debt VS Total AssetsAXSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

AXSM has an Altman-Z score of 2.91. This is not the best score and indicates that AXSM is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of AXSM (2.91) is better than 71.13% of its industry peers.
AXSM has a Debt/Equity ratio of 3.48. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 3.48, AXSM is doing worse than 81.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.48
Debt/FCF N/A
Altman-Z 2.91
ROIC/WACCN/A
WACC10.18%
AXSM Yearly LT Debt VS Equity VS FCFAXSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 2.03 indicates that AXSM has no problem at all paying its short term obligations.
AXSM has a worse Current ratio (2.03) than 60.31% of its industry peers.
AXSM has a Quick Ratio of 1.96. This is a normal value and indicates that AXSM is financially healthy and should not expect problems in meeting its short term obligations.
AXSM has a Quick ratio of 1.96. This is comparable to the rest of the industry: AXSM outperforms 41.75% of its industry peers.
Industry RankSector Rank
Current Ratio 2.03
Quick Ratio 1.96
AXSM Yearly Current Assets VS Current LiabilitesAXSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.56% over the past year.
Looking at the last year, AXSM shows a very strong growth in Revenue. The Revenue has grown by 72.16%.
EPS 1Y (TTM)9.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.28%
Revenue 1Y (TTM)72.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%61.95%

3.2 Future

Based on estimates for the next years, AXSM will show a very strong growth in Earnings Per Share. The EPS will grow by 39.56% on average per year.
Based on estimates for the next years, AXSM will show a very strong growth in Revenue. The Revenue will grow by 46.11% on average per year.
EPS Next Y39.19%
EPS Next 2Y50.12%
EPS Next 3Y52.37%
EPS Next 5Y39.56%
Revenue Next Year59.8%
Revenue Next 2Y59.88%
Revenue Next 3Y57.74%
Revenue Next 5Y46.11%

3.3 Evolution

AXSM Yearly Revenue VS EstimatesAXSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AXSM Yearly EPS VS EstimatesAXSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AXSM. In the last year negative earnings were reported.
AXSM is valuated quite expensively with a Price/Forward Earnings ratio of 67.54.
AXSM's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AXSM is cheaper than 67.53% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.71, AXSM is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 67.54
AXSM Price Earnings VS Forward Price EarningsAXSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXSM Per share dataAXSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

AXSM's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as AXSM's earnings are expected to grow with 52.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.12%
EPS Next 3Y52.37%

More info and screens

0

5. Dividend

5.1 Amount

AXSM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXSOME THERAPEUTICS INC

NASDAQ:AXSM (7/22/2025, 8:00:01 PM)

After market: 102.5 -0.05 (-0.05%)

102.55

-7.13 (-6.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners75.3%
Inst Owner Change-1.29%
Ins Owners1.39%
Ins Owner Change-0.14%
Market Cap5.05B
Analysts86.4
Price Target179.12 (74.67%)
Short Float %10.09%
Short Ratio6.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.43%
Min EPS beat(2)-48.67%
Max EPS beat(2)9.8%
EPS beat(4)2
Avg EPS beat(4)-13.73%
Min EPS beat(4)-48.67%
Max EPS beat(4)9.8%
EPS beat(8)2
Avg EPS beat(8)-22.16%
EPS beat(12)5
Avg EPS beat(12)-8.88%
EPS beat(16)8
Avg EPS beat(16)-4.81%
Revenue beat(2)0
Avg Revenue beat(2)-0.84%
Min Revenue beat(2)-1.03%
Max Revenue beat(2)-0.65%
Revenue beat(4)1
Avg Revenue beat(4)0.11%
Min Revenue beat(4)-1.69%
Max Revenue beat(4)3.79%
Revenue beat(8)5
Avg Revenue beat(8)2.25%
Revenue beat(12)8
Avg Revenue beat(12)26.69%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.52%
PT rev (3m)-0.71%
EPS NQ rev (1m)-2.48%
EPS NQ rev (3m)-4.97%
EPS NY rev (1m)-2.07%
EPS NY rev (3m)-9.67%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)-0.22%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)-0.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 67.54
P/S 11.68
P/FCF N/A
P/OCF N/A
P/B 94.91
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.77
EYN/A
EPS(NY)1.52
Fwd EY1.48%
FCF(TTM)-2.41
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS8.78
BVpS1.08
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.64%
ROE -523.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.49%
FCFM N/A
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 3.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.17%
Cap/Sales 0.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.03
Quick Ratio 1.96
Altman-Z 2.91
F-Score5
WACC10.18%
ROIC/WACCN/A
Cap/Depr(3y)9.27%
Cap/Depr(5y)133.06%
Cap/Sales(3y)0.56%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.28%
EPS Next Y39.19%
EPS Next 2Y50.12%
EPS Next 3Y52.37%
EPS Next 5Y39.56%
Revenue 1Y (TTM)72.16%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%61.95%
Revenue Next Year59.8%
Revenue Next 2Y59.88%
Revenue Next 3Y57.74%
Revenue Next 5Y46.11%
EBIT growth 1Y6.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.92%
EBIT Next 3Y60.13%
EBIT Next 5Y46.22%
FCF growth 1Y-31.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.93%
OCF growth 3YN/A
OCF growth 5YN/A